The Manchester company behind the IONA non-invasive prenatal test has signed an agreement to offer the ground-breaking treatment in Thailand.
Premaitha Health’s IONA, which detects Downs Syndrome and other genetic diseases in unborn children by using a blood sample, will be used in the Center for Medical Genomics at Ramathibodi Hospital, Mahidol University, partnering with the Thailand Center of Excellence for Life Sciences.
Due to its high level of accuracy, the IONA test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow up diagnostic procedures which are both costly and resource intensive; and carry a small risk of miscarriage.
Dr Stephen Little, CEO of Premaitha, said: “We are delighted to have expanded our global footprint of laboratory customers to now include Thailand and that women in the country will increasingly be able to benefit from our safe and accurate non-invasive test. Asia Pacific is a region in which we believe there is significant potential for non-invasive prenatal testing – to secure our first operational laboratory in Asia is an important strategic milestone.”
See the article in full at TheBusinessDesk.com